Connective tissue growth factor (CTGF), is a critical mediator in the progression of fibrosis and related serious diseases. FibroGen is developing Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of CTGF and in turn can benefit in Idiopathic Pulmonary Fibrosis (IPF) along with Pancreatic Cancer, and Duchenne Muscular Dystrophy
FibroGen recently announced positive top line data for Pamrevlumab from phase 2 randomized, double-blind, placebo-controlled study and two combination safety sub-studies of Pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF)
PharmGPS® distinguished Pamrevlumab from other emerging drugs months in advance, based on initial Phase II data regarding its efficacy, safety and dosing regimen, as one of the front runners for treating patients with IPF. Pamrevlumab, using PharmGPS® proprietary algorithm, was anticipated to emerge as one of the top clinical assets in IPF space. With comparable safety profile to approved therapies and better efficacy than molecules in clinical development, it outperformed around 16 other molecules in the similar phase.
Pamrevlumab is expected to represent a significant landmark for IPF patient community, as is evident from its excellent clinical data in Phase II
PharmGPS® analysis revealed advantages of targeting CTGF in IPF. As in IPF, CTGF is a key mediator in the progression of fibrosis. It is induced by transforming growth factor beta (TGFbeta) and it is also hypothesized to act as a mediator of some profibrotic effects of TGFbeta. There are substantial evidences around the profibrotic effect of CTGF and its contribution to lung fibrosis through transcriptional activation of Col1a2. Blocking strategies has revealed the signaling mechanisms involved. These findings show CTGF to be a rational target for therapy in fibrotic diseases such as IPF
Currently, ProMetic Life Sciences (PBI-4050), in addition to FibroGen (Pamrevlumab), is also developing CTGF inhibitor for the treatment of IPF. Although both the candidates are almost equally efficacious and safe, PBI-4050 will enjoy the benefit of being in oral form. However, FibroGen achieved a significant advantage in trial confidence by testing the drug in more number of patients and backed with the recent clinical data, Pamrevlumab is likely to outperform PBI-4050.
The clinical trial results published for Pamrevlumab and PBI-4050 to date are summarized below: